Adverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […]

Related Keywords

Monaco ,James Paul Scopa ,Adverum Biotechnologie ,Newtyn Management ,Citigroup Inc ,Capital Management ,Adverum Biotechnologies Inc ,Adverum Biotechnologies Company Profile ,Adverum Biotechnologies ,Free Report ,Moderate Buy ,Get Free Report ,Director James Paul Scopa ,Asset Management ,Apexium Financial ,Adverum Biotechnologies Daily ,Nasdaq Advm ,Advm ,Medical ,Initiated Coverage ,Hc Wainwright ,